Osimertinib and Capmatinib Combination Therapy to Overcome MET Y1003N-Mediated Resistance in EGFR-Mutant NSCLC: A Case Report by Molly Wilgucki, DO, Vincent Yeung, MD, Grace Ho, MD, Gabriela L. Bravo Montenegro, MD, Greg Jones, Joshua E. Reuss, MD, Stephen V. Liu, MD, Chul Kim, MD, MPH

Get full text